Host Control and Injection Order Identified in Long Terminal Repeats Comprising 10% of Phage Genomes Used for Staphylococcus aureus Treatment
Background
Antibiotic resistance is one of the most serious threats facing modern medicine. Phage therapy research is actively underway to utilize bacteriophages (viruses that infect bacteria) as medicines to control virulent pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA). Among phages targeting Staphylococcus, viruses belonging to the subfamily Twortvirinae possess massive genomes of approximately 140 kilobases (kb) and have demonstrated excellent bactericidal efficacy. Four genera—Kayvirus, Silviavirus, Sepunavirus, and Twortvirus—are representative and are already approaching clinical trials.
Even with clinical applications imminent, a significant portion of the genes in these phage genomes remains difficult to predict functionally through homology analysis alone. This is because more than half of the decoded phage genome sequences consist of unknown genes. Among them, the long terminal repeats (LTRs), which account for approximately 10% of the viral particle DNA, are the regions with the highest genetic variation and have been least studied. Because early genome analysis technologies were vulnerable to decoding repetitive sequences, LTR sequences of around 14kb were often completely omitted during assembly or placed in incorrect locations on genomic maps. Consequently, this genomic region, which may hold the key to therapeutic efficacy, has long been left in an analytical blind spot.
Key Findings
This study, which integrated comparative genomics, transcriptomic profiling, and bacteria-phage interaction data, elucidated the molecular functions and genetic structures of LTRs that had remained obscure. It was revealed that the LTR region contains a cluster of early genes expressed by the phage immediately after invading the host bacteria. These genes are responsible for rapidly seizing the transcriptional system within the bacteria, safely establishing the phage genome, and neutralizing the defense systems activated by the bacteria. They serve as key mechanisms helping the phage gain the upper hand in the initial survival competition with the host.
Simultaneously, by integrating genomic analysis data, the researchers determined for the first time the directionality of infection, identifying which end of the viral genome enters the host cell first upon infection. The order of DNA end entry provides a physical clue directly linked to the transcriptional regulation sequence in which viral genes are expressed sequentially over time.
From an evolutionary perspective, the LTR region showed extreme dynamism. Nucleotide sequences targeted by bacterial anti-phage defense mechanisms were found to be disproportionately concentrated in the LTR, and phages were responding through gene acquisition, loss, and rapid mutation. This intense arms race between bacteria and viruses is unfolding on the stage of this 10% repetitive sequence region. It has been confirmed with concrete evidence that the LTR is not merely a structural end of Twortvirinae phages, but a key regulatory and evolutionary hub driving host adaptation and survival.
Significance and Outlook
By elucidating the role of phage LTRs, which had been relegated to the realm of the unknown, this study provides clear molecular targets for the development of next-generation personalized antibacterial therapeutics. Since it has been identified that bacterial defense evasion genes and early transcriptional regulators are concentrated in the LTR, future phage improvement work based on synthetic biology, aimed at specific pathogen strains, is expected to become much more precise. The LTR has emerged as an essential manipulation site in genome engineering aimed at expanding host range or improving bactericidal speed.
However, many challenges remain before this leads to actual therapeutic phage design. Much remains to be elucidated regarding the three-dimensional structures and biochemical reaction pathways of individual proteins secreted by genes within the LTR. Follow-up experimental verification is also required regarding how LTR-derived proteins penetrate defense barriers when encountering various strains of the bacterial immune system. Establishing long-range genome analysis techniques capable of handling complex repetitive sequences without error as a clinical quality standard is also cited as a prerequisite for commercialization.
Staphylococcal bacteriophages with proven therapeutic efficacy in anti-staphylococcal therapy have large (~140 kb) genomes and belong to subfamily Twortvirinae. Representatives of four genera (Kayvirus, Silviavirus, Sepunavirus, and Twortvirus) are the most intensively studied and are advancing toward clinical applications. However, the functions of many of their genes remain unknown and cannot be predicted from sequence homology alone. The least explored and most diverse genomic regions are the long terminal repeats (LTRs), which comprise ~10% of the virion DNA. These regions were often omitted from early genome assemblies or misplaced in genomic maps. Only recent studies have shown that LTRs encode genes expressed immediately upon infection and involved in host takeover, genome establishment, and interactions with bacterial defense systems, highlighting their critical role in successful infection during phage therapy. This review synthesizes current knowledge on the genomic architecture, transcriptional organization, and molecular functions of LTR regions in Twortvirinae phages. By integrating comparative genomics with recent transcriptomic and phage-host interaction studies, we identify LTRs as key regulatory and evolutionary hubs in Twortvirinae biology and highlight major knowledge gaps concerning their roles in bacterial immunity and phage genome evolution. The enrichment of LTRs in targets of bacterial anti-phage defense systems, together with their dynamic evolution through gene gain, loss, and diversification, suggests a central role in phage adaptation to diverse hosts. Finally, our synthesis of available data allows us, for the first time, to infer which end of the phage genome enters the host cell first during infection.
This research serves as a compass for dramatically improving the safety and bactericidal efficacy of treatment pipelines for multidrug-resistant Staphylococcus aureus infections. In clinical settings, phage therapeutics are frequently neutralized because they fail to breach bacterial defense systems; by identifying the defense evasion factors present in the LTR, phage agents can be pre-selected to specifically target strains from infected patients.
Biotechs operating synthetic phage production platforms can enhance killer factors that paralyze host metabolism immediately upon entry into the bacteria by targeting the LTR region for gene editing. In the mass production process of therapeutic phages, consistent bactericidal efficacy will be ensured by establishing genome quality control standards that perfectly preserve terminal repeats, which are prone to omission.